By: Christina Y. Weng, MD, MBA (Chair); Sophie J. Bakri, MD; David A. Eichenbaum, MD, FAAO; Glenn Yiu, MD, PhD
This course has expired. You can still review the content but course credit is no longer available.
Content Source
This continuing medical education (CME) activity captures content from a virtual roundtable discussion.
Activity Description
This supplement summarizes an in-depth discussion into the available treatment options for diabetic retinopathy (DR) and diabetic macular edema (DME), as well as the challenges faced by retina specialists and patients in the current environment of COVID-19. The faculty also reviews emerging therapies and the potential they have for longer duration and improved outcomes.
Target Audience
This certified CME activity is designed for retina specialists.
This activity is supported by an unrestricted educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
This educational activity is provided by Evolve Medical Education LLC (Evolve).
Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Christina Y. Weng, MD, MBA (Chair)
Associate Professor of Ophthalmology
Baylor College of Medicine
Houston, Texas
Sophie J. Bakri, MD
Professor and Chair
Department of Ophthalmology
Mayo Clinic
Rochester, MN
David A. Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
Tampa, Florida
Glenn Yiu, MD, PhD
Associate Professor
University of California—Davis
Sacramento, California
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Christina Y. Weng, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera Sciences, Allergan/AbbVie, DORC, Genentech, Novartis, Regeneron Pharmaceuticals, and Regenxbio.
Sophie J. Bakri, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Allergan, Alimera, Apellis, Eyepoint Pharmaceuticals, Regenexbio, Genentech, Kala Pharmaceuticals, Novartis, and Roche.
David A. Eichenbaum, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, EyePoint Pharmaceuticals, Genentech, Gyroscope, IvericBio, Kodiak, Notal Vision, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu, Gemini, Genentech, Gyroscope, lonis, lvericBio, Kodiak, Mylan, NGM, Novartis, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Allergan, Bayer, DORC, EyePoint Pharmaceuticals, Genentech, and Novartis.
Glenn Yiu, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Clearside Biomedical, Genentech, Iridex, Intergalactic Therapeutics, NGM Biopharmaceutical, Regeneron, Topcon.
The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Retina Today, or Genentech.